Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Hepatitis A vaccine inactivated; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live; Varicella zoster virus vaccine live
- Indications Measles; Mumps; Rubella
- Focus Adverse reactions; Registrational
- Acronyms MMR-162
- Sponsors GlaxoSmithKline; GSK
- 06 Jun 2022 According a GlaxoSmithKline media release, company announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.